Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019 
MarketWatch (press release)
GlobalData, the industry analysis specialist, has released its new report, "Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Myelofibrosis ...

and more » 

Rex, Sanchez among Jets players, coaches trying to help fan in need of bone ... 
Washington Post
Manganiello of Wayside, NJ, was diagnosed last month with acute myelofibrosis, a rare condition in which progressive scarring of the bone marrow impairs its ability to make blood cells. His only chance is a bone marrow transplant, and Jets coach Rex ...
Defensive coordinator Mike Pettine to host event in Eatontown to benefit Jets fan The Star-Ledger - NJ.com
Rex, Sanchez trying to help Jets fan in need kgw.com

all 58 news articles » 

YM BioSciences Reports Operational and Financial Results for the Third Quarter ... 
MarketWatch (press release)
"In the past few months we delivered robust Phase I/II results for our JAK1/JAK2 inhibitor, CYT387, in patients with myelofibrosis and we raised an additional $80 million principally to support the further advancement of this drug," said Dr. Nick ...

and more » 

Incyte's CEO Bank of America Merrill Lynch 2012 Health Care Conference ... 
Seeking Alpha
It's approved for use in patients with intermediate or high risk myelofibrosis and it's the first and only product to be approved by the FDA for myelofibrosis. So, it's also the first to be approved for any indication of a new class of drug which ...

and more » 

YM Biosciences: The Next Way To Get Long Myelofibrosis 
Seeking Alpha
YM Biosciences Inc. (YMI) has stated that it is currently in discussions with the FDA to agree on a protocol for the Phase III clinical trial design for its lead product candidate CYT387, for the treatment of myelofibrosis (MF).

 

Incyte's Potential Blockbuster Pipeline Asset Makes It An Attractive Takeover ... 
Seeking Alpha
Its products include: INCB18424 (oral) for Prostate Cancer (Metastatic Prostate Cancer), Hematological Malignancies (Primary Myelofibrosis), Psoriasis and multiple myeloma; INCB28050 (oral) for Rheumatoid arthritis and Cancer; INCB13739 and INCB19602 ...

 

Promedior Appoints Suzanne L. Bruhn, Ph.D., as President and Chief Executive ... 
SunHerald.com
Dr. Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis, and retinal diseases.
New chief takes helm at Promedior and steers a course for Boston FierceBiotech

all 11 news articles » 

Analyst says Incyte's pipeline makes it attractive takeover candidate 
Proactive Investors USA & Canada
Its products include: INCB18424 (oral) for Prostate Cancer (Metastatic Prostate Cancer), Hematological Malignancies (Primary Myelofibrosis), Psoriasis and multiple myeloma; INCB28050 (oral) for Rheumatoid arthritis and Cancer; INCB13739 and INCB19602 ...

and more » 

Novartis receives CHMP backing for myelofibrosis drug 
Zenopa
Novartis has been granted a recommendation for European regulatory approval of its drug Jakavi for the treatment of disease-related splenomegaly or symptoms in myelofibrosis patients. The European Medicines Agency's Committee for Medicinal Products for ...

 

'Pay it forward' Stem cell transplant recipient from Dover encourages ... 
Foster's Daily Democrat
Andrea Wise, 51, was diagnosed with myelofibrosis, a serious bone marrow disorder that disrupts a body's normal production of blood cells, last August and received a stem cell transplant at Massachusetts General Hospital in January.

and more »